Fundraising Fox

Eikon Therapeutics

NASDAQ: EIKN

Hayward, US · Founded 2019 · Delaware corporation · 434 employees on LinkedIn · 3 known investors

Biotech

Founders & leadership

RM
Roger M. PerlmutterExecutive

Board

JWJoshua Wolfe
Joshua Wolfein𝕏Board directorPartner and Co-Founder at Lux Capital
DB
Dror BermanBoard director
JT
James TananbaumBoard director
LC
Leon ChenBoard director
AGAdam Goulburn
Adam Goulburnin𝕏Board directorFounder and Managing Partner at Dimension Capital
RH
Robbie HuffinesBoard director
KF
Kenneth FrazierBoard director
RW
Robin WashingtonBoard director

Investors · 3

Foresite CapitalWest Hollywood
Lux CapitalNew York · $100K – $100M
Dimension CapitalreportedSan Francisco · $1M – $10M

Funding

SEC filings, press & company announcements

$1.1B disclosed across 4 of 5 rounds · 2021–2026

▶$350.7MraisedFeb 2025 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robbie HuffinesDirector
  • Joshua WolfeDirector
  • Dror BermanDirector
  • James TananbaumDirector
  • Leon ChenDirector
  • Kenneth FrazierDirector
  • Robin WashingtonDirector
  • Roger M. PerlmutterExecutive Officer, Director
Offering amount
$400M
Amount sold
$350.7M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$140.8MraisedJun 2023 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robin WashingtonDirector
  • Dan AndersonExecutive Officer
  • Ashish KheterpalExecutive Officer
  • Kenneth FrazierDirector
  • Josh WolfeDirector
  • Dror BermanDirector
  • Russ BermanExecutive Officer
  • Leon ChenDirector
  • James TananbaumDirector
  • Roy BanesExecutive Officer
  • Roger M. PerlmutterExecutive Officer, Director
  • Benjamin ThornerExecutive Officer
  • Alfred BowieExecutive Officer
  • Barbara HowesExecutive Officer
Offering amount
$535M
Amount sold
$140.8M
Minimum investment
$33.7K
First sale
May 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$517.8MraisedJan 2022 · 43 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alfred BowieExecutive Officer
  • Roger M. PerlmutterExecutive Officer, Director
  • Adam GoulburnDirector
  • James TananbaumDirector
  • Leon ChenDirector
  • Benjamin ThornerExecutive Officer
  • Dror BermanDirector
Offering amount
$525M
Amount sold
$517.8M
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$102.5MraisedMay 2021 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James TananbaumDirector
  • Leon ChenExecutive Officer, Director
  • Adam GoulburnDirector
  • Roger M PerlmutterExecutive Officer, Director
  • Dror BermanDirector
Offering amount
$107.8M
Amount sold
$102.5M
First sale
May 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Eikon Therapeutics went on to found or lead other companies.

Josh WolfeDirectorFounded Genocea BiosciencesAdam GoulburnDirectorFounded Kallyope

In the news

FMR LLC Expands Eikon Therapeutics Inc (EIKN) Stake Despite Post-IPO Slidegurufocus.com · Aug 2026Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO | Reutersreuters.com · Feb 2026Eikon sets $274M goal for upcoming stock market debutfiercebiotech.com · Jan 2026

Frequently asked questions

Who are Eikon Therapeutics's investors?
Eikon Therapeutics's investors include Foresite Capital, Lux Capital, Dimension Capital.
How much funding has Eikon Therapeutics raised?
Eikon Therapeutics has disclosed $1.1B raised across 4 of its 5 known rounds.
Where is Eikon Therapeutics headquartered?
Eikon Therapeutics is headquartered in Hayward, US.